Search results
Results from the WOW.Com Content Network
Advanced glycation end products (AGEs) are proteins or lipids that become glycated as a result of exposure to sugars. [1] They are a bio-marker implicated in aging and the development, or worsening, of many degenerative diseases , such as diabetes , atherosclerosis , chronic kidney disease , and Alzheimer's disease .
The manipulation of the glyoxalase system in mice retina has shown there is a potential for targeting the glyoxalase system to use as a therapeutic treatment for RD by lowering the production of AGEs. [9] Oxidative stress can lead to worsening neurological diseases such as Alzheimer's, Parkinson's, and Autism Spectrum Disorder.
Sorbitol may also glycate nitrogens on proteins, such as collagen, and the products of these glycations are referred-to as AGEs - advanced glycation end-products. AGEs are thought to cause disease in the human body, one effect of which is mediated by RAGE (receptor for advanced glycation end-products) and the ensuing inflammatory responses induced.
Schematic of the relation between an immunoglobulin and RAGE Schematic of the RAGE gene and its products. RAGE (receptor for advanced glycation endproducts), also called AGER, is a 35 kilodalton transmembrane receptor [5] of the immunoglobulin super family which was first characterized in 1992 by Neeper et al. [6] Its name comes from its ability to bind advanced glycation endproducts (), which ...
Pages in category "Advanced glycation end-products" The following 8 pages are in this category, out of 8 total. This list may not reflect recent changes. A.
N(6)-Carboxymethyllysine (CML), also known as N ε-(carboxymethyl)lysine, is an advanced glycation endproduct (AGE). CML has been the most used marker for AGEs in food analysis. CML has been the most used marker for AGEs in food analysis.
Alagebrium (formerly known as ALT-711, dimethyl-3-N-phenacylthiazolium chloride) was a drug candidate developed by Alteon, Inc.It was the first drug candidate to be clinically tested for the purpose of breaking the crosslinks caused by advanced glycation endproducts (AGEs), thereby reversing one of the main mechanisms of aging. [1]
Pimagedine was under development as a drug for kidney diseases by the pharmaceutical company Alteon (now known Synvista Therapeutics Inc.) that was founded in 1986. [2] In 1987, Alteon acquired a license to intellectual property relating to AGE inhibition from Rockefeller University. [3]